SARCLUNG trial : Multicenter Propensity-Matched Analysis Comparing Stereotactic Body Radiotherapy vs. Metastasectomy for Sarcoma Lung Metastases
Principal Investigator PI:
Dr. med. Siyer Roohani
siyer.roohani@charite.de
Co-Principal Investigators (Co-PIs):
Dr. med. Samuel Moritz Vorbach
samuel.vorbach@i-med.ac.at
Dr. Mateusz Spalek, MD, PhD
Mateusz.spalek@nio.gov.pl
Short Background:
Soft tissue sarcomas often metastasize to the lungs. Surgery is the standard, but SBRT is emerging as a promising, less invasive alternative. Comparative data between both treatments remain limited.
Study design:
● Multi-center, retrospective, propensity-matched cohort study comparing SBRT vs. metastasectomy for lung metastases from sarcoma.
● Collaboration between the DEGRO Working Groups for Radiosurgery & Stereotactic Radiotherapy and young DEGRO. Endorsed and supported by the Arbeitsgemeinschaft Radiologische Onkologie.
Study objective:
Primary: Assess if SBRT is non-inferior to surgery for 12-month local control.
Secondary: Compare lung metastasis-free survival (LMFS), progression-free survival (PFS), overall survival (OS), freedom from systemic therapy, and toxicity.
Project status:
Ongoing. Recruitment and data collection in progress across multiple international centers.